BIOTECHA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 12,612,995 | 15,260,891 | 38,428,467 | 58,360,319 | 50,270,649 | 36,474,889 | 43,002,146 | 30,023,440 |
| Profit before tax | 2,827,911 | 3,114,116 | 9,796,505 | 14,865,633 | 10,768,738 | 4,431,993 | 6,185,441 | 3,214,031 |
| Net profit | 2,455,753 | 2,644,595 | 8,410,130 | 12,439,062 | 9,220,565 | 3,346,282 | 4,849,544 | 3,040,305 |
| Equity | 6,831,059 | 4,048,980 | 9,742,272 | 15,181,333 | 17,401,899 | 17,748,181 | 19,597,725 | 21,638,030 |
| Liabilities | 2,331,480 | 2,672,089 | 9,026,406 | 8,174,004 | 5,266,033 | 9,580,674 | 17,146,488 | 12,865,728 |
| Non-current assets | 3,590,980 | 255,581 | 453,748 | 1,014,954 | 3,076,784 | 7,658,037 | 14,844,490 | 14,721,685 |
| Current assets | 5,679,970 | 6,441,314 | 18,080,137 | 23,876,390 | 21,227,082 | 21,229,142 | 25,904,670 | 21,791,145 |
| Total assets | 9,270,950 | 6,696,895 | 18,533,885 | 24,891,344 | 24,303,866 | 28,887,179 | 40,749,160 | 36,512,830 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 6,789,883 | 4,904,838 | 6,324,528 |
| Social insurance contributions | - | - | - | - | - | 696,209 | 831,242 | 884,108 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +34.8% | +21.0% | +151.8% | +51.9% | -13.9% | -27.4% | +17.9% | -30.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 26.5% | 39.5% | 45.4% | 50.0% | 37.9% | 11.6% | 11.9% | 8.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 35.9% | 65.3% | 86.3% | 81.9% | 53.0% | 18.9% | 24.7% | 14.1% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 19.5% | 17.3% | 21.9% | 21.3% | 18.3% | 9.2% | 11.3% | 10.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 22.4% | 20.4% | 25.5% | 25.5% | 21.4% | 12.2% | 14.4% | 10.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.7 | 0.9 | 0.5 | 0.3 | 0.5 | 0.9 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 569,006 | 422,935 | 924,132 | 1,079,082 | 715,596 | 510,733 | 598,638 | 408,946 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BIOTECHA - Social security debts
The company had no debts to Sodra
BIOTECHA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-07-28 | 2025-07-28 | 21400.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BIOTECHA, UAB (code 300630105) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated €30.02M in revenue and €3.04M in net profit, with a net profit margin of 10.1%. Revenue declined by 30.2% year on year, and the 2-year revenue change was -17.7%, showing a clear slowdown after the stronger 2024 result. The company’s revenue was €36.47M in 2023, rose to €43.00M in 2024, and then fell in 2025, while net profit moved from €3.35M to €4.85M and then to €3.04M over the same period. At the end of 2025, total assets stood at €36.51M, equity at €21.64M, and liabilities at €12.87M. Key ratios remained solid, with ROE at 14.1%, ROA at 8.3%, debt-to-equity at 0.59, and asset turnover at 0.82x. Revenue per employee was €411.3K.